The FDA is proposing to remove semaglutide, tirzepatide, and liraglutide from the list of ingredients that outsourcing pharmacies can use to make bulk drug products. This change would prevent compounding pharmacies from manufacturing cheaper generic versions of these weight-loss and diabetes drugs.

• •FDA proposes excluding semaglutide, tirzepatide, liraglutide from 503B bulks list
• •Move would bar outsourcing facilities from compounding bulk versions of these drugs
• •Targets cheaper compounded alternatives to branded weight-loss and diabetes drugs

The FDA is proposing to remove semaglutide, tirzepatide, and liraglutide from the list of drugs that pharmacies can bulk-order for compounding (making custom doses). This would force patients to use brand-name versions of these weight-loss and diabetes drugs instead of cheaper pharmacy-made copies.

• •FDA proposes excluding semaglutide, tirzepatide, and liraglutide from 503B bulks list
• •Move would block pharmacies from bulk-ordering these APIs for compounding
• •Patients would be pushed toward brand-name versions

The FDA plans to remove semaglutide, tirzepatide, and liraglutide from the list of drugs that large-scale pharmacies can legally make in bulk (called 503B compounding). This change would force patients to buy these weight-loss and diabetes drugs from manufacturers instead of cheaper pharmacy-made versions.

• •FDA plans to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list
• •Move would block large-scale pharmacy bulk compounding of these GLP-1s
• •Patients would need to source from manufacturers rather than compounded versions

The FDA is proposing to remove semaglutide, tirzepatide, and liraglutide from the list of drugs that pharmacies can use to make bulk copies under 503B rules (a program that lets facilities make custom medicines). This change would prevent large-scale compounding of these weight-loss and diabetes drugs, likely pushing patients toward branded versions.

• •FDA proposes excluding semaglutide, tirzepatide, liraglutide from 503B bulks list
• •Change would block large-scale compounding of these GLP-1 drugs
• •Patients would be pushed toward branded versions

The FDA is proposing to remove weight-loss drugs from a list of medicines that pharmacies are allowed to make themselves (called compounding). This change could force patients to buy more expensive brand-name versions instead of cheaper pharmacy-made copies.

• •FDA proposing to exclude weight-loss drugs from pharmacy compounding list
• •Change would restrict pharmacies from making their own versions
• •Patients would face more expensive brand-name options

The FDA is stepping up enforcement actions against pharmacies that make cheaper copycat versions of GLP-1 weight-loss drugs like tirzepatide and semaglutide. The agency is tightening rules on which ingredients pharmacies can legally compound without brand-name drug company approval.

• •FDA stepping up enforcement against pharmacies compounding GLP-1 copycats
• •Action targets compounded tirzepatide and semaglutide
• •Agency tightening rules on ingredients pharmacies can compound without brand approval

Tirzepatide (the drug in Mounjaro and Zepbound) reduced the risk of death from heart and blood vessel problems by 62% in a study. This finding suggests the weight-loss drug may protect people's hearts, not just help them lose weight.

• •Tirzepatide linked to 62% lower risk of cardiovascular death in study
• •Finding applies to Mounjaro and Zepbound, both tirzepatide brands

A cardiologist discussed how tirzepatide (a dual-action weight-loss and diabetes drug) performed better than dulaglutide (another diabetes drug) in protecting the heart and kidneys in a clinical study. The comparison highlights tirzepatide's broader benefits beyond weight loss.

• •Tirzepatide outperformed dulaglutide on cardiorenal outcomes in a clinical study
• •Steven Nissen, MD discussed the comparison in a Q&A format
• •Findings position tirzepatide's benefits beyond weight loss

Counterfeit tirzepatide (a weight-loss and diabetes drug) was discovered in India's Haryana region, prompting Eli Lilly to warn people to buy the drug only with a prescription from a doctor. The company is trying to stop fake versions from reaching patients.

• •Counterfeit tirzepatide discovered in Haryana, India
• •Eli Lilly issued a safety warning urging prescription-only purchases
• •Company taking action to prevent fake versions reaching patients

Eli Lilly rejected a recommendation from Australia's PBS (the agency that decides which medicines get government funding) about how to price and distribute Mounjaro in the country. The decision means negotiations over coverage and affordability for this tirzepatide weight-loss drug are still ongoing.

• •Eli Lilly rejected a PBS recommendation regarding Mounjaro in Australia.
• •PBS subsidy negotiations for tirzepatide remain unresolved.

A comparison study suggests that semaglutide (Ozempic) may preserve muscle better than tirzepatide (Mounjaro) when people use these weight-loss drugs. The finding could matter for people choosing between the two medications.

• •Comparison study suggests semaglutide preserves muscle better than tirzepatide
• •Finding relevant for patients choosing between Ozempic and Mounjaro for weight loss

A new study looked at how tirzepatide (Mounjaro) and semaglutide (Ozempic/Wegovy) compare in terms of cost and health results for people with obesity. The research helps show which drug might be better for patients and their wallets.

• •Study compares tirzepatide (Mounjaro) vs semaglutide (Ozempic/Wegovy) in obesity
• •Analysis covers both cost and health outcomes

A Louisiana bill aims to let Medicaid (a health program for low-income people) cover three popular weight-loss drugs: Ozempic, Wegovy, and Mounjaro. The change could make these expensive medications available to more people who need them but can't pay out-of-pocket.

• •Louisiana bill would expand Medicaid coverage to Ozempic, Wegovy and Mounjaro
• •Targets access for low-income patients currently unable to afford the drugs

A medical case study describes a patient who developed high blood calcium levels while taking tirzepatide (a weight-loss and diabetes drug) and calcium supplements together. The report suggests doctors should watch for this rare combination effect in patients on tirzepatide.

• •Case report describes hypercalcemia in a patient on tirzepatide plus calcium supplementation
• •Authors recommend clinician vigilance for this drug-supplement interaction
• •Published as a Cureus case report

• •GoodRx publishes comparison of retatrutide versus tirzepatide